利巴韦林联合聚乙二醇干扰素α-2a注射液对慢性丙型肝炎患者的疗效及安全性  

Efficacy and Safety of Ribavirin Combined with Pegylated Interferonα-2a Injection in Patients with Chronic Hepatitis C

作　　者：张娟 ZHANG Juan(Department of the 9th Liver Disease,Dalian Sixth People's Hospital,Dalian 116000,China)

机构地区：[1]大连市第六人民医院肝病九科,辽宁大连116000

出　　处：《中国医药指南》2021年第12期75-76,共2页Guide of China Medicine

摘　　要：目的探讨利巴韦林联合聚乙二醇干扰素α-2a注射液对慢性丙型肝炎患者的疗效及安全性。方法选取2018年1月至2019年1月在大连市第六人民医院肝病九科住院治疗的80例慢性丙型肝炎患者,随机分为试验组和对照组,每组40例。对照组采取利巴韦林注射液联合普通干扰素治疗,试验组采取聚乙二醇干扰素α-2a注射液联合利巴韦林注射液治疗,记录并比较两组患者的临床疗效和不良反应发生情况。结果试验组的临床总应答比例高于对照组,差异有统计学意义(P<0.05);试验组患者的不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论利巴韦林联合聚乙二醇干扰素α-2a注射液对慢性丙型肝炎患者的疗效显著,安全性较高。Objective To investigate the efficacy and safety of ribavirin combined with pegylated interferonα-2a injection in patients with chronic hepatitis C.Methods From January 2018 to January 2019,80 patients with chronic hepatitis C hospitalized in dalian sixth people's hospital were randomly divided into experimental group and control group,with 40 patients in each group.The control group was treated with ribavirin injection combined with common interferon,and the experimental group was treated with pegylated interferonα-2a injection combined with ribavirin injection.The clinical efficacy and the incidence of adverse reactions were recorded and compared between the two groups.Results The proportion of total clinical response in experimental group was higher than that in control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in experimental group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion Ribavirin combined with pegylated interferonα-2a injection has significant efficacy and high safety in patients with chronic hepatitis C.

关 键 词：慢性丙型肝炎 利巴韦林 聚乙二醇干扰素Α-2A 不良反应 

分 类 号：R512.63[医药卫生—内科学]